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ABSTRACT
Objective: There is a debate regarding the use of disease-
speciﬁc versus generic instruments for health-related quality
of life (HRQOL) measures. We tested the psychometric prop-
erties of HRQOL measures using the Diabetes-39 (D-39) and
the Medical Outcomes Study 36-Item Short-Form Health
Survey (SF-36).
Methods: This was a cross-sectional study collecting data
from 280 patients in Taiwan. Exploratory factor analysis was
conducted to evaluate construct validity of the two instru-
ments. Known-groups validity was examined using labora-
tory indicators (fasting, 2-hour postprandial plasma glucose,
and hemoglobin A1c), presence of diabetic complications
(retinopathy, nephropathy, neuropathy, diabetic foot disor-
der, cardiovascular and cerebrovascular disorders), and psy-
chosocial variables (sense of well-being and self-reported
diabetes severity). Overall discriminative power of the two
instruments was evaluated using the C-statistic.
Results: Three distinct factors were extracted through factor
analysis. These factors tapped all subscales of the D-39, four
physical subscales of the SF-36, and four mental subscales of
the SF-36, respectively. Compared with the SF-36, the D-39
demonstrated superior known-groups validity for 2-hour
postprandial plasma glucose groups but was inferior for
complication groups. Compared with the SF-36, the D-39
discriminated better between self-reported severity known
groups, but was inferior between well-being groups. In
overall discriminative power, the D-39 discriminated better
between laboratory known groups. The SF-36, however, was
superior in discriminating between complication known
groups.
Conclusions: For psychometric properties, the D-39 and the
SF-36 were superior to each other in different regards. The
combined use of a disease-speciﬁc instrument and a generic
instrument may be a useful strategy for diabetes HRQOL
assessment.
Keywords: diabetes, health-related quality of life, psychomet-
ric property.
Introduction
Diabetes mellitus is a group of metabolic diseases char-
acterized by hyperglycemia resulting from defects in
insulin secretion and/or insulin resistance. The preva-
lence of diabetes across all age groups worldwide was
estimated to be 2.8% in 2000 and projected to be
4.4% by 2030 [1]. The chronic hyperglycemia of dia-
betes is associated with long-term damage to multiple
organ systems, including macrovascular and microvas-
cular diseases. Adults with diabetes have an age-
adjusted mortality rate estimated to be twice that of
people without diabetes [2].
Conventional outcome assessment for diabetes
relies on laboratory indicators, primarily on hemoglo-
bin A1c (HbA1c) and complications of diseases. The
exclusive reliance on clinical outcomes, however, does
not necessarily reﬂect patients’ perceptions of their
heath [3,4]. Treatment regimens that require changes
of lifestyles and behaviors can inﬂuence patients’ daily
functioning and well-being. Therefore, health-related
quality of life (HRQOL) is increasingly used as an
outcome indicator alongside traditional biomedical
measures.
Several instruments are available for measuring
HRQOL in diabetes, including generic and diabetes-
speciﬁc instruments. Generic instruments are designed
to investigate aspects of health that are of universal
importance, and allow comparisons of HRQOL
among different groups of patients. By contrast,
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diabetes-speciﬁc instruments attempt to capture the
speciﬁc impact of diabetes on patients’ functioning and
well-being, and could be more sensitive to small clini-
cally important differences. Reviews have shown that
the dimensions covered by diabetes-speciﬁc instru-
ments vary, but generally include physical functioning,
psychological functioning, social-role fulﬁllment, dia-
betes control, and treatment satisfaction [5–7]. Among
instruments, the Medical Outcomes Study 36-Item
Short-Form Health Survey (the SF-36) is a commonly
used generic instrument for diabetes [8,9], while the
Diabetes-39 (the D-39) has been demonstrated to have
good psychometric properties and can be recom-
mended [5,7].
Although various instruments are available to
measure HRQOL in diabetes, psychometric evidence
does not indicate whether it is preferable to use
generic or diabetes-speciﬁc instrument individually, or
in combination [10–12]. The knowledge gap in the
instrument selection is partly due to incomplete psy-
chometric validation of many instruments during their
development. HbA1c, a measure reﬂecting the longer-
term glycemic control, is commonly used as the gold
standard to validate the instruments. Evidence of the
association between HbA1c and HRQOL scores,
however, tends to be weak [13]. It is possible that
validation could be improved by including other labo-
ratory indicators (e.g., fasting plasma glucose [FPG]
and postprandial plasma glucose [PPG]) that better
account for the impact of ﬂuctuations and acute
increase of glycemia (hyperglycemic spikes) on daily
functioning [14,15].
One study has suggested that FPG and PPG were
more sensitive to detect metabolic changes (e.g., hyper-
glycemia) than HbA1c for type 2 diabetes patients
[16]. Other studies reported that postprandial hyperg-
lycemia may contribute more signiﬁcantly to the
development of diabetic complications (especially
cardiovascular diseases) than fasting hyperglycemia
[14,17].
Hyperglycemic symptoms and diabetic complica-
tions are major determinants of HRQOL [18,19].
Other nonglucose indicators that reﬂect poor control
of diabetes, such as renal damage, using serum creati-
nine (Cr) and glomerular ﬁltration rate (GFR), could
also be applied for validation. In addition, the use of
psychosocial variables, such as the sense of overall
well-being, might help compare generic and diabetes-
speciﬁc instruments.
The purpose of this study was to compare psycho-
metric properties of a diabetes-speciﬁc HRQOL instru-
ment (the D-39) against a generic instrument (the
SF-36) using samples collected in Taiwan. Speciﬁcally,
we evaluated the psychometric properties of both
instruments using several clinical and psychosocial
variables, including: 1) laboratory indicators: FPG
2-hour PPG, HbA1c, microalbuminuria, Cr, and GFR;
2) complications of diabetes: retinopathy, nephropa-
thy, neuropathy, diabetic foot disorder, cardiovascular,
and cerebrovascular diseases; and 3) sense of overall
well-being and self-reported diabetes severity. The
comparisons of generic versus diabetes-speciﬁc instru-
ments will be helpful in guiding instrument selection in
HRQOL research and clinical practice.
Methods
Participants and Data Collection
Data were collected from the Taiwan Diabetes Health
Survey, an initiative funded by the Taiwan Department
of Health (DOH) to systematically translate and adapt
HRQOL instruments for diabetes patients. In the ﬁrst
year of this project, we conducted face-to-face inter-
views to collect data using the D-39 and the SF-36. In
total, we interviewed 280 type 1 and type 2 diabetes
patients seeking outpatient services in a DOH-
afﬁliated teaching hospital between February and April
2006.
Laboratory and clinical assessments and HRQOL
measures were collected at the same time for each
patient and tested using the same method for all
patients. Laboratory indicators were FPG, 2-hour
PPG, HbA1c, microalbuminuria, Cr, and GFR. Diabe-
tes complications were abstracted from medical
records. We identiﬁed a number of complications,
including retinopathy (none vs. background, prolifera-
tive, or decreased vision), nephropathy (none vs. pro-
teinuria, or dialysis), neuropathy (none vs. present),
diabetic foot disorders (none vs. foot ulceration, sepsis,
or amputation), cardiovascular complications (none
vs. angina, or previous myocardial infarction or con-
gestive heart failure), and cerebrovascular complica-
tions (none vs. transient ischemic attack, or stroke)
[20].
HRQOL Measures
The D-39 is a 39-item instrument that was designed to
assess HRQOL for patients with type 1 and type 2
diabetes. This instrument covers the dimensions of
energy and mobility (EM), diabetes control (DC),
anxiety and worry (AW), social burden (SB), and
sexual functioning (SF) [21,22]. Items are adminis-
tered using seven response categories, ranging from
not affected at all (score = 1) to extremely affected
(score = 7). The subscale scores are calculated by
summing responses across all items in the same sub-
scale, with high scores representing poor HRQOL. A
summary score is further derived from the ﬁve subscale
scores of the D-39. The Taiwan version of the D-39 (in
Chinese) was translated and culturally adapted in
2004 using a standardized approach and has demon-
strated good psychometric properties [23].
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The SF-36 is a generic HRQOL instrument measur-
ing a broad range of HRQOL concepts, including
physical functioning (PF), role limitations due to physi-
cal health problems (RP), bodily pain (BP), general
health perceptions (GH), vitality (VT), social function-
ing (SF), role limitations due to emotional problems
(RE), and mental health (MH). Subscale scores range
from 0 to 100, with high scores representing better
HRQOL. Two summary scores are also calculated: a
physical component score (PCS) and mental compo-
nent score (MCS), with scores standardized to a
normal distribution (mean = 50 and standard devia-
tion [SD] = 10) [24]. The Taiwan version of the SF-36
(in Chinese) was translated in 1996 and has shown
acceptable psychometric properties [25].
Psychometric Analyses
Psychometric properties between the D-39 and the
SF-36 were examined using internal consistency, con-
struct validity, known-groups validity, and overall dis-
criminative validity [26].
The internal consistency of each subscale was
assessed by Cronbach’s alpha coefﬁcient. Construct
validity of the D-39 versus the SF-36 was assessed
using exploratory factor analysis, which investigates
intercorrelations among subscales of both instruments.
Because approximately 3.5% of the subjects (N = 10)
were missing on one or two subscale scores and these
subjects were not statistically different from those who
had no missing values in the variables of age, gender,
and clinical measures (e.g., HbA1c, 2-hour PPG, etc.),
we simply imputed the missing values using the mean
subscale score. According to the rules of thumb (4–10
observations per variables), the use of 280 subjects in
this study is sufﬁcient for conducting exploratory
factor analysis [27]. We speciﬁcally applied the princi-
pal factors approach with a promax rotation, assum-
ing extracted factors from the subscales were
correlated, for all subscales of the instruments. Homo-
geneous subscales that measure the same HRQOL
construct were assumed to be convergent within the
same factor and discriminate themselves from other
factors that comprise homogeneous subscales. The
number of factors extracted from both instruments
was determined by eigenvalues greater than 1 and
review of scree plots. Because both instruments
measure generic and diabetes-speciﬁc concepts of
HRQOL, we hypothesized that three factors would be
extracted corresponding to a physical impairment
construct (mainly physical subscales of the SF-36), a
mental health/psychological dissatisfaction (mainly
mental subscales of the SF-36), and a diabetes-speciﬁc
stress factor (mainly the D-39 subscales), respectively.
Known-groups validity of the instruments was
examined to assess the extent to which subscales can
discriminate between clinically meaningful patient
groups, including laboratory diagnosis and diabetic
complication groups. Laboratory diagnosis known
groups were deﬁned for those patients whose values of
laboratory measures were less versus more than the
accepted cutoff points: 110 mg/dl for FPG, 140 mg/dl
for 2-hour PPG, 7.0% for HbA1c, 1.5 mg/dl for Cr,
and 60 ml/min/1.73 m2 for GFR [28]. GFR is fre-
quently used to estimate the level of kidney function.
In this study, the Cockroft–Gault equation was used to
estimate GFR, based the patient’s Cr, age, gender, and
body weight [29]. We used the cutoff of GFR of less
than 60 ml/min/1.73 m2 to deﬁne the presence of
chronic kidney disease [29].
Diabetes morbidity known groups were deﬁned for
those patients who were diagnosed with versus with-
out complications of retinopathy, nephropathy, neur-
opathy, diabetic foot diseases, cardiovascular diseases,
and cerebrovascular diseases, respectively. A summary
indicator—the number of diabetes complications—
was also generated to represent the overall impact of
complications. For investigating known-groups valid-
ity, we dichotomized this index at the median value for
the number of complications. Cohen’s effect size (ES)
was calculated to measure the magnitude of known-
group validity (unit: SD) [30], deﬁned as the differ-
ences in subscale scores between known groups (e.g.,
HbA1c of less vs. more than 7.0%) divided by the
pooled SD of both groups.
We also included two psychosocial variables in the
comparison of the D-39 and the SF-36: 1) sense of
overall well-being; and 2) self-reported diabetes sever-
ity. Sense of overall well-being is a single question that
was designed to assess patients’ overall perception of
their quality of life. We hypothesized that this item
would discriminate better for generic HRQOL (the
SF-36) than for diabetes stress scales (the D-39). Self-
reported diabetes severity is a single question that
assesses patients’ appraisal of diabetes severity. We
hypothesized this item would discriminate better for
the D-39 than for the SF-36. To investigate known-
group validity, we dichotomized each of the two mea-
sures at their median values.
We assessed overall discriminative validity by the
instrument’s ability to discriminate patients with labo-
ratory values higher versus lower than the cutoff point
as well as those with versus without a speciﬁc diabetes
complication. Discriminative power was measured by
calculating the area under a receiver operator charac-
teristic (ROC) curve (i.e., the C-statistic). An advan-
tage of using the C-statistic is that it can take into
account the performance of all subscales simulta-
neously. The C-statistic ranges from 0.5 (no discrimi-
native power) to 1 (perfect discriminative power).
Conventionally, we adopted the values of 0.7 or more,
0.8 or more, and 0.9 or more for the acceptable, good,
and excellent discriminative ability, respectively. Sepa-
rate C-statistics of speciﬁc clinical indicators for the
D-39 and the SF-36 were compared using a univariate
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z-test [31,32]. In this study, all of the analyses were
performed using the STATA 9.02 [33].
Results
Characteristics of Subjects
Table 1 shows the patients’ characteristics (N = 280).
The mean age was 62.9 years (SD 10.6) and 53%
were male. For laboratory measures, mean FPG was
149 mg/dl (SD 44), mean 2-hour PPG was 194 mg/dl
(SD 74), and mean HbA1c was 7.5% (SD 1.8). For
diabetes complications, 38% had nephropathy, 20%
had retinopathy, 17% had diabetic foot disorder, 15%
had neuropathy, and 13% and 7% had cardiovascular
and cerebrovascular diseases, respectively. For type of
treatment, the majority of the subjects (79%) were on
lifestyle modiﬁcation plus oral medication.
Scale Reliability
Internal consistency estimated using the Cronbach’s
alpha exceeded the acceptable level of 0.7 [30] for all
subscales of both instruments, except social function-
ing of the SF-36. Alpha coefﬁcients for the D-39 and
the SF-36 subscales ranged from 0.82 to 0.93 and 0.61
to 0.88, respectively.
Construct Validity
The distributions of subscale scores for the SF-36 and
the D-39 were normal or near normal (with Skewness
and Kurtosis measures around 0 and 3, respectively),
which meets the basic requirement of conducting
factor analysis [27]. Table 2 shows the construct valid-
ity of the D-39 versus the SF-36, examined using
exploratory factor analysis. Results of factor analysis
suggest that three distinct factors were extracted, each
with an eigenvalue of more than 1. The proportion of
variance for subscales explained by the extracted
factors (i.e., communality) was acceptable, ranging
from 0.43 (sexual functioning of the D-39) to 0.88
(energy and mobility of the D-39). After the promax
rotation, all subscales of the D-39 loaded on the ﬁrst
factor (diabetes-speciﬁc stress). Four subscales of the
SF-36 relevant to physical functioning (PF, RP, BP, and
GH) loaded on the second factor (physical function-
ing). Four subscales of the SF-36 relevant to mental
health (VT, SF, RE, and MH) aggregated in the third
factor (mental health). In addition, a D-39 summary
score, PCS andMCS of the SF-36 loaded on the factors
of diabetes-speciﬁc stress, physical functioning, and
mental health, respectively. The intercorrelations
among three extracted factors were moderate, with the
range between 0.48 (diabetes-speciﬁc stress and physi-
cal functioning) and 0.58 (diabetes-speciﬁc stress and
mental health). Taken together, these ﬁndings suggest
that two instruments may measure different HRQOL
constructs.
Table 1 Patients’ characteristics (N = 280)
Social demographic variables
Mean (SD) or
percentage
Age (years), mean (SD) 62.9 (10.6)
<55,% 17.5
55–59.9 21.2
60–64.9 19.3
65–69.9 15.7
70–74.9 13.5
75 12.8
Gender, %
Male 52.9
Female 47.1
Education, %
Uneducated 10.6
Primary and junior high schools 43.1
Senior high school 19.7
College 22.6
Graduate 4.0
Marriage, %
Married 79.8
Divorced 1.5
Widowed 14.0
Never marred 4.8
Living, %
Alone 8.3
With family 84.6
With others 7.1
Employment status, %
Yes 35.0
No 65.0
Type of treatment, %
Lifestyle modiﬁcation 2.1
Lifestyle modiﬁcation plus oral medication 78.9
Lifestyle modiﬁcation plus insulin 6.1
Lifestyle modiﬁcation plus oral medication plus
insulin
12.9
Laboratory diagnoses
Fasting plasma glucose, mg/dl 149.0 (43.9)
2-hour postprandial plasma glucose, mg/dl 194.3 (73.8)
Hemoglobin A1c,% 7.5 (1.8)
Microalbuminuria, mg/24 h 91.4 (227.5)
Creatinine, mg/dl 1.1 (0.3)
Glomerular ﬁltration rate (GFR), ml/min/1.73 m2 64.0 (21.3)
GFR stages, %
Stage 1 (90) 12.3
Stage 2 (60–89) 42.6
Stage 3 (30–59) 41.9
Stage 4 (15–29) 3.3
Low-density lipoprotein cholesterol, mg/dl 109.8 (28.5)
Hypertension (140/90 mmHg), % 52.1
Complications, %
Retinopathy 20.1
Nephropathy 37.5
Neuropathy 14.5
Diabetic foot complications 16.7
Cardiovascular complications 12.5
Cerebrovascular complications 6.6
Diabetes duration (years), mean (SD) 8.7 (6.4)
Body weight classiﬁcation,* %
Underweight (BMI < 18.5) 0.4
Normal weight (18.5 BMI < 23) 23.2
Overweight (23 BMI < 25) 31.4
Obesity (BMI 25) 45.0
Type of diabetes,† %
Type 1 (age < 30 years old and BMI < 23) 1.1
Type 2 (either age 30 years old or BMI 23,
or both)
98.9
*Classiﬁcation of body-mass index (BMI) [56].
†Classiﬁcation of type of diabetes [57].
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Known-Groups Validity
Table 3 shows known-groups validity investigated
using laboratory indicators. After adjusting for age,
gender, education background, and diabetes dura-
tion, the extent to which subscales discriminated
between 2-hour PPG groups was greater than that
between FPG and HbA1c groups. In comparisons
between instruments, for 2-hour PPG known groups,
subscales of the D-39 had better discriminative ability
(especially diabetic control, energy and mobility sub-
scales, and a D-39 summary score with effect sizes of
0.33, 0.30, and 0.30, respectively) compared with the
SF-36. For FPG and HbA1c known groups, all sub-
scales in both instruments demonstrated ignorable
Table 2 Construct validity of the D-39 and SF-36 examined using exploratory factor analysis*
Factor 1:
Diabetes-speciﬁc stress
Factor 2:
Physical functioning
Factor 3:
Mental health Communality
D-39†
DC39 0.90‡ 0.09 -0.07 0.81
EM39 0.71 -0.37 0.02 0.88
SB39 0.85 0.00 -0.10 0.83
AW39 0.81 0.06 -0.14 0.76
SF39 0.69 -0.01 0.09 0.43
SUM39 0.95 -0.05 -0.04 0.99
SF-36†
PF36 -0.02 0.93 -0.11 0.78
RP36 0.04 0.62 0.34 0.70
BP36 -0.06 0.76 0.01 0.64
GH36 -0.06 0.52 0.22 0.49
VT36 -0.07 0.28 0.62 0.73
SF36 -0.03 0.09 0.69 0.58
RE36 0.04 0.17 0.73 0.61
MH36 -0.15 -0.06 0.84 0.88
PCS36 0.00 1.09 -0.21 0.99
MCS36 -0.08 -0.29 1.08 0.99
Factor intercorrelations
Factor 1 1
Factor 2 0.48 1
Factor 3 0.58 0.54 1
*Based on factor analysis with a promax rotation.
†For the D-39: DC39, diabetes control; EM39, energy and mobility; SB39, social burden;AW39, anxiety and worry; SF39, sexual functioning; SUM39, D-39 summary scores. For
the SF-36: PF36, physical functioning; RP36, role limitations due to physical problems; BP36, bodily pain; GH36, general health perceptions;VT36, vitality; SF36, social functioning;
RE36, role limitations due to emotional problems; MH36, mental health; PCS36, physical component scores; MCS36, mental component scores.
‡Values in columns 2 to 4 represent factor loadings.
Table 3 Known-groups validity of the D-39 and SF-36 examined using laboratory diagnosis indicators
Fasting plasma
glucose
2-hour postprandial
plasma glucose
Hemoglobin
A1c Microalbuminuria Creatinine
Glomerular
ﬁltration rate
D-39*
DC39 -0.10†‡§ 0.33 0.13 0.06 0.30 0.19
EM39 -0.01 0.30 0.02 0.02 0.53 0.16
SB39 -0.22 0.17 0.03 -0.04 0.27 0.05
AW39 -0.20 0.17 0.05 0.02 0.17 0.03
SF39 0.11 0.22 -0.03 0.02 0.45 -0.02
SUM39 -0.06 0.30 0.03 0.02 0.45 0.09
SF-36*
PF36 -0.01 0.18 -0.02 0.10 0.42 0.11
RP36 0.09 0.21 -0.04 -0.02 0.63 0.30
BP36 -0.11 0.03 -0.11 -0.07 0.58 0.04
GH36 -0.08 0.16 -0.13 -0.07 0.42 -0.06
VT36 0.03 0.24 -0.04 0.12 0.49 0.22
SF36 <0.01 0.10 -0.02 <0.01 0.27 0.15
RE36 -0.14 0.14 -0.10 -0.08 0.49 0.25
MH36 -0.08 0.19 -0.20 -0.12 0.53 0.04
PCS36 0.02 0.15 -0.03 0.05 0.57 0.12
MCS36 -0.09 0.16 -0.13 -0.09 0.39 0.15
*For the D-39: DC39, diabetes control; EM39, energy and mobility; SB39, social burden;AW39, anxiety and worry; SF39, sexual functioning; SUM39, D-39 summary scores. For
the SF-36: PF36, physical functioning; RP36, role limitations due to physical problems; BP36, bodily pain; GH36, general health perceptions;VT36, vitality; SF36, social functioning;
RE36, role limitations due to emotional problems; MH36, mental health; PCS36, physical component scores; MCS36, mental component scores.
†Values represent effect sizes: small (0.2–0.49), moderate (0.5–0.79), and large (0.8).
‡Negative values mean poor laboratory diagnosis value was associated with better HRQOL.
§Adjusting for age, gender, education, and diabetes duration.
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(<0.2) or unexpected signs for effect sizes (i.e., poorer
laboratory diagnosis values associated with better
HRQOL scores). For Cr known groups, the SF-36
(especially physical subscales) showed greater dis-
criminative ability than the D-39. For example, the
effect sizes by the SF-36 PCS, role limitation due to
physical problems, and pain subscales for Cr known
groups were 0.57, 0.63, and 0.58, respectively.
Table 4 shows known-groups validity examined
with the individual and summarized measures of dia-
betes complications. For individual complications,
after adjusting for age, gender, education background,
and diabetes duration, in general the SF-36 discrimi-
nated better than the D-39. This was especially
obvious for the physical aspects of the SF-36 for neu-
ropathy, cardiovascular, and cerebrovascular disease
groups. Of particular note, the SF-36’s physical func-
tioning subscale and PCS demonstrated moderate
effect sizes (0.5–0.79) between cardiovascular disease
known groups. The SF-36’s physical functioning and
vitality subscales, as well as PCS demonstrated large
effect sizes (0.8) between cerebrovascular disease
groups. The SF-36 and the D-39 discriminated equiva-
lently for retinopathy and diabetic foot complication
known groups. With respect to a summary com-
plication indicator, results suggest that the SF-36
demonstrates better discriminative ability than the
D-39, especially in physical aspects of HRQOL. For
example, the effect sizes of the physical functioning
subscale and PCS were 0.32 and 0.38, respectively,
which were larger than for any subscales of the D-39.
Table 5 shows known-groups validity investigated
with psychosocial variables. For overall well-being
known groups, the SF-36 had slightly better discrimi-
native ability compared with the D-39, especially for
mental aspects of HRQOL. For example, the effect
sizes of the vitality and mental health subscales of the
SF-36 were 0.64 and 0.60, which were higher than for
any of the D-39 subscales. In contrast, for self-reported
diabetes severity known groups, the D-39 demon-
Table 4 Known-groups validity of the D-39 and SF-36 examined using diabetes complications
Retinopathy Nephropathy Neuropathy
Diabetic foot
complications
Cardiovascular
complications
Cerebrovascular
complications
All six
complications
D-39*
DC39 0.12†‡§ 0.16 0.32 0.39 0.40 0.22 0.22
EM39 0.22 0.13 0.41 0.45 0.45 0.59 0.27
SB39 0.01 0.07 0.12 0.27 0.43 0.44 0.23
AW39 0.11 0.09 0.30 0.33 0.29 0.40 0.17
SF39 -0.09 0.13 -0.29 0.11 0.29 0.04 0.21
SUM39 0.06 0.13 0.17 0.35 0.44 0.38 0.15
SF-36*
PF36 0.28 0.19 0.42 0.37 0.52 1.14 0.32
RP36 0.04 0.17 0.27 0.13 0.31 0.40 0.29
BP36 0.19 0.11 0.50 0.33 0.21 0.55 0.22
GH36 0.04 0.19 0.15 0.28 0.34 0.28 0.18
VT36 0.16 0.22 0.49 0.50 0.34 1.17 0.22
SF36 0.03 -0.02 0.03 0.08 -0.11 0.58 0.01
RE36 0.10 0.10 0.29 0.19 0.04 0.35 0.12
MH36 -0.05 -0.06 0.26 0.26 0.07 0.50 0.01
PCS36 0.24 0.25 0.44 0.34 0.53 0.84 0.38
MCS36 -0.05 -0.03 0.16 0.18 -0.09 0.43 0.06
*For the D-39: DC39, diabetes control; EM39, energy and mobility; SB39, social burden;AW39, anxiety and worry; SF39, sexual functioning; SUM39, D-39 summary scores. For
the SF-36: PF36, physical functioning; RP36, role limitations due to physical problems; BP36, bodily pain; GH36, general health perceptions;VT36, vitality; SF36, social functioning;
RE36, role limitations due to emotional problems; MH36, mental health; PCS36, physical component scores; MCS36, mental component scores.
†Values represent effect sizes: small (0.2–0.49), moderate (0.5–0.79), and large (0.8).
‡Negative values mean presence of complications was associated with better HRQOL.
§Adjusting for age, gender, education, and diabetes duration.
Table 5 Known-groups validity of the D-39 and SF-36 using
psychosocial variables
Sense of overall
well-being
Self-reported diabetes
severity
D-39*
DC39 0.45†‡ 0.83
EM39 0.54 0.90
SB39 0.36 0.80
AW39 0.46 0.65
SF39 0.25 0.59
SUM39 0.52 0.88
SF-36*
PF36 0.42 0.52
RP36 0.39 0.70
BP36 0.39 0.50
GH36 0.61 0.75
VT36 0.64 0.86
SF36 0.45 0.81
RE36 0.46 0.69
MH36 0.60 0.75
PCS36 0.43 0.59
MCS36 0.57 0.82
*For the D-39: DC39, diabetes control; EM39, energy and mobility; SB39, social
burden; AW39, anxiety and worry; SF39, sexual functioning; SUM39, D-39 summary
scores. For the SF-36: PF36, physical functioning; RP36, role limitations due to physical
problems; BP36, bodily pain; GH36, general health perceptions; VT36, vitality; SF36,
social functioning; RE36, role limitations due to emotional problems; MH36, mental
health; PCS36, physical component scores; MCS36, mental component scores.
†Values represent effect sizes: small (0.2–0.49),moderate (0.5–0.79), and large (0.8).
‡Adjusting for age, gender, education, and diabetes duration.
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strated slightly better discriminated ability than the
SF-36. For example, the effect sizes for the energy and
mobility subscale and a D-39 summary score were 0.9
and 0.88, which were higher than for any subscales of
the SF-36.
Overall Discriminative Validity
The overall discriminative power of the D-39 and the
SF-36 using the indicators of laboratory diagnosis and
complication is shown in Table 6. The D-39 demon-
strated slightly higher C-statistics than the SF-36 (either
for eight subscales or for two component scales) for
glucose indicators, including FPG, 2-hour PPG and
HbA1c. The C-statistics for the SF-36 were equivalent
to or slightly higher than the D-39 for the Cr and GFR
indicators. After adjusting for age, gender, education,
and diabetes duration, the D-39 demonstrated signiﬁ-
cantly a higher C-statistic for 2-hour PPG than the
SF-36’s two component scores (0.70 vs. 0.63;P < 0.05).
For complications, the SF-36 revealed higher
C-statistics than the D-39 across all types of condi-
tions, except neuropathy. Especially, for cardiovascular
disease known groups, the C-statistic of the SF-36
eight subscales was signiﬁcantly higher than that of the
D-39 ﬁve subscales (0.76 vs. 0.66; P < 0.05). Likewise,
for the summary complication known groups, the
C-statistics of the SF-36 eight subscales and two com-
ponent scales were signiﬁcantly higher than those of
D-39 subscales (0.72 vs. 0.62 and 0.72 vs. 0.62,
respectively; all comparisons with P < 0.05). After
adjusting for age, gender, education, and diabetes
duration, the SF-36 demonstrated equivalent or
slightly higher C-statistics than the D-39 (all compari-
sons with P > 0.05).
For psychosocial variables, the D-39 and SF-36
demonstrated similar overall discriminative ability
between the overall well-being groups and self-
reported severity groups (all comparisons with
P > 0.05).
Treatment Effect and HRQOL Measures
Figure 1 shows the association of HRQOL and four
types of diabetes treatments—lifestyle modiﬁcation
alone, lifestyle modiﬁcation plus oral medication (LO),
lifestyle modiﬁcation plus insulin (LI), and lifestyle
modiﬁcation, oral medication plus insulin (LOI). For
the D-39, after adjusting for age, gender, education,
diabetes duration, and complications, subjects treated
with the LOI were associated with poorer HRQOL in
all subscales (except sexual functioning) than the LI
group, followed by the LO group. Subjects treated by
lifestyle modiﬁcation alone showed the best HRQOL.
Of particular note, contrasting to those receiving lif-
estyle modiﬁcation alone, subjects in the LOI group
had large (effect size: 0.8) and moderate (effect size:
0.5–0.79) impact on the energy/mobility and diabetes
control, respectively.
For the SF-36 PCS, compared with those receiving
lifestyle modiﬁcation alone, subjects in the LOI group
had greater impact on HRQOL (moderate effect size)
than those in either the LI or the LO group (small
effect size). By contrast, type of treatment had ignor-
able impact (effect size of less than 0.2) on the SF-36
MCS.
Discussion
In this study, we compared psychometric properties of
a diabetes-speciﬁc HRQOL instrument (the D-39)
versus a generic instrument (the SF-36) using samples
collected in Taiwan. Our study differed from previous
studies of this type in that we evaluated the HRQOL
measures against a variety of laboratory and clinical
indicators (FPG, 2-hour PPG, HbA1c, microalbumin-
uria, Cr, GFR, and diabetes complications) and psy-
chosocial variables (sense of overall well-being and
self-reported diabetes severity), and applying different
psychometric methods.
Construct validity suggests that the D-39 and SF-36
may measure different HRQOL construct. Three dis-
tinct factors were extracted through factor analysis,
each tapping all subscales of the D-39, four physical
subscales of the SF-36, and four mental subscales
of the SF-36, respectively. Known-groups validity
revealed that the D-39 was superior to the SF-36 for
discriminating 2-hour PPG and HbA1c known groups.
There were larger differences seen for 2-hour PPG
groups than for HbA1c groups. For complications
known groups, however, the subscales of the SF-36
generally discriminated better than the D-39. Com-
pared with the SF-36, the D-39 discriminated better
between the self-reported severity groups, but was
inferior for sense of well-being groups. For overall
discriminative power, the D-39 discriminated better
between laboratory groups. In contrast, the SF-36 dis-
criminated better between complication groups.
Previous studies have used HbA1c as the glycemic
control indicator to validate HRQOL measures. Evi-
dence, however, is mixed regarding the association of
HbA1c with HRQOL. Although some studies have
suggested that good glycemic control was associated
with better HRQOL [34–36], other studies have not
[4,12,37–39]. Although the inconsistent ﬁndings may
in part be attributed to the use of different HRQOL
instruments (especially, generic vs. disease-speciﬁc)
[13], another reason may be that clinical indicators
such as HbA1c are relatively insensitive to the differ-
ences in HRQOL measures.
Basically, HbA1c is an integrated summary of blood
glucose levels during the preceding 2 to 3 months. By
contrast, 2-hour PPG captures the peaks and troughs
in glucose concentrations that represent short-term
ﬂuctuations in metabolic control. Epidemiologic
456 Huang et al.
Ta
bl
e
6
O
ve
ra
ll
pe
rf
or
m
an
ce
of
th
e
D
-3
9
an
d
SF
-3
6
ex
am
in
ed
us
in
g
th
e
C
-s
ta
tis
tic
*
Fa
st
in
g
pl
as
m
a
2-
ho
ur
po
st
pr
an
di
al
H
em
og
lo
bi
n
G
lo
m
er
ul
ar
La
bo
ra
to
ry
di
ag
no
se
s
gl
uc
os
e
pl
as
m
a
gl
uc
os
e
A
1c
M
ic
ro
al
bu
m
in
ur
ia
C
re
at
in
in
e
ﬁl
tr
at
io
n
ra
te
1)
H
R
Q
O
L
sc
al
es
D
-3
9
(5
su
bs
ca
le
s)
0.
62
0.
65
0.
58
0.
57
0.
72
0.
60
SF
-3
6
(8
su
bs
ca
le
s)
0.
61
0.
62
0.
55
0.
63
0.
72
0.
68
SF
-3
6
(P
C
S/
M
C
S)
0.
55
0.
59
0.
54
0.
61
0.
72
0.
62
2)
H
R
Q
O
L
sc
al
e
pl
us
ag
e,
ge
nd
er
,e
du
ca
tio
n,
an
d
di
ab
et
es
du
ra
tio
n
D
-3
9
(5
su
bs
ca
le
s)
0.
64
0.
70
†
0.
68
0.
65
0.
85
0.
85
SF
-3
6
(8
su
bs
ca
le
s)
0.
63
0.
65
0.
69
0.
68
0.
86
0.
86
SF
-3
6
(P
C
S/
M
C
S)
0.
58
0.
63
0.
68
0.
65
0.
84
0.
84
C
om
pl
ic
at
io
ns
R
et
in
op
at
hy
N
ep
hr
op
at
hy
N
eu
ro
pa
th
y
D
ia
be
tic
fo
ot
co
m
pl
ic
at
io
ns
C
ar
di
ov
as
cu
la
r
co
m
pl
ic
at
io
ns
C
er
eb
ro
va
sc
ul
ar
co
m
pl
ic
at
io
ns
A
ll
si
x
co
m
pl
ic
at
io
ns
1)
H
R
Q
O
L
sc
al
es
D
-3
9
(5
su
bs
ca
le
s)
0.
65
0.
59
0.
76
0.
66
0.
66
0.
72
0.
62
SF
-3
6
(8
su
bs
ca
le
s)
0.
68
0.
67
0.
72
0.
69
0.
76
‡
0.
84
0.
72
‡
SF
-3
6
(P
C
S/
M
C
S)
0.
66
0.
64
0.
69
0.
67
0.
73
0.
75
0.
72
§
2)
H
R
Q
O
L
sc
al
e
pl
us
ag
e,
ge
nd
er
,e
du
ca
tio
n,
an
d
di
ab
et
es
du
ra
tio
n
D
-3
9
(5
su
bs
ca
le
s)
0.
76
0.
69
0.
80
0.
76
0.
75
0.
79
0.
82
SF
-3
6
(8
su
bs
ca
le
s)
0.
76
0.
73
0.
80
0.
77
0.
80
0.
85
0.
83
SF
-3
6
(P
C
S/
M
C
S)
0.
75
0.
71
0.
76
0.
76
0.
77
0.
81
0.
82
Ps
yc
ho
so
ci
al
va
ri
ab
le
s
Se
ns
e
of
ov
er
al
l
w
el
l-b
ei
ng
Se
lf-
re
po
rt
ed
di
ab
et
es
se
ve
ri
ty
1)
H
R
Q
O
L
sc
al
es
D
-3
9
(5
su
bs
ca
le
s)
0.
72
0.
79
SF
-3
6
(8
su
bs
ca
le
s)
0.
74
0.
78
SF
-3
6
(P
C
S/
M
C
S)
0.
71
0.
75
2)
H
R
Q
O
L
sc
al
e
pl
us
ag
e,
ge
nd
er
,e
du
ca
tio
n,
an
d
di
ab
et
es
du
ra
tio
n
D
-3
9
(5
su
bs
ca
le
s)
0.
74
0.
79
SF
-3
6
(8
su
bs
ca
le
s)
0.
75
0.
80
SF
-3
6
(P
C
S/
M
C
S)
0.
73
0.
78
*C
-s
ta
tis
tic
ra
ng
es
fr
om
0.
5
to
1.
0
(n
o
di
sc
ri
m
in
at
iv
e
to
pe
rf
ec
t
di
sc
ri
m
in
at
iv
e
po
w
er
).
Va
lu
es
of

0.
7,

0.
8,
an
d

0.
9
re
pr
es
en
t
ac
ce
pt
ab
le
,g
oo
d,
an
d
ex
ce
lle
nt
di
sc
ri
m
in
at
iv
e
va
lid
ity
,r
es
pe
ct
iv
el
y.
† C
-s
ta
tis
tic
fo
r
D
-3
9
is
hi
gh
er
th
an
SF
-3
6
tw
o
co
m
po
ne
nt
sc
or
es
(P
C
S
an
d
M
C
S)
(P
<
0.
05
).
‡ C
-s
ta
tis
tic
fo
r
SF
-3
6
ei
gh
t
su
bs
ca
le
s
(P
F,
R
P,
BP
,G
H
,V
T,
SF
,R
E,
an
d
M
H
)
is
hi
gh
er
th
an
D
-3
9
(P
<
0.
05
).
§ C
-s
ta
tis
tic
fo
r
SF
-3
6
tw
o
co
m
po
ne
nt
sc
or
es
(P
C
S
an
d
M
C
S)
is
hi
gh
er
th
an
D
-3
9
(P
<
0.
05
).
PC
S,
ph
ys
ic
al
co
m
po
ne
nt
sc
or
e;
M
C
S,
m
en
ta
lc
om
po
ne
nt
sc
or
e;
PF
,p
hy
si
ca
lf
un
ct
io
ni
ng
;R
P,
ro
le
lim
ita
tio
ns
du
e
to
ph
ys
ic
al
pr
ob
le
m
s;
BP
,b
od
ily
pa
in
;G
H
,g
en
er
al
he
al
th
pe
rc
ep
tio
ns
;V
T,
vi
ta
lit
y;
SF
,s
oc
ia
lf
un
ct
io
ni
ng
;R
E,
ro
le
lim
ita
tio
ns
du
e
to
em
ot
io
na
l
pr
ob
le
m
s;
M
H
,m
en
ta
lh
ea
lth
.
Diabetes-Speciﬁc versus Generic HRQOL Measures 457
studies have suggested that normal HbA1c levels
could be associated with postprandial hyperglycemia,
leading to a substantially increased risk of death from
macrovascular diseases [14,40,41], especially for
cardiovascular complications [17,42,43]. In most
instances, PPG levels increase before and faster than
FPG [44–46]. As a result, increased postprandial gly-
cemia is related to greater risk than fasting hypergly-
cemia for the development of cardiovascular diseases
and all-cause mortality [42,47,48]. Together with our
results, this suggests the use of 2-hour PPG in addition
to HbA1c to test the validity of diabetes HRQOL
measures.
In contrast to blood sugar abnormalities, diabetes
complications can cause a signiﬁcant impact on
HRQOL [3,49,50]. For people with poor glycemic
control, the major risk is the development of chronic
problems that affect multiple organ systems. Lloyd
et al. found that patients with more diabetes compli-
cations (particularly three or more complications)
tended to report poor HRQOL [51]. Several studies
have shown that the subscales of HRQOL measures
[11,21,52] (typically physical HRQOL [53]) can dis-
criminate the presence and absence of diabetes com-
plications. Consistent with other studies [37,49], our
results support the value of cardiovascular and cere-
brovascular diseases known groups. Interestingly, this
was not true for retinopathy and nephropathy. It is
possible that changes in retinal blood vessels or pro-
teinuria (typically microalbuminuria) may appear
early in diabetes and may not be associated with symp-
toms for many years.
We were able to compare known-groups validity
using laboratory and clinical measures, and found that
given the same instruments, effect sizes for laboratory
measures were smaller than for diabetes complica-
tions. This may be due to the fact that 1) not all people
with diabetes suffer from complications; and 2) clinical
symptoms (e.g., hypoglycemia) and events (e.g.,
stroke) are more evident to patients than laboratory
abnormalities.
It has long been debated whether generic or
disease-speciﬁc instruments should be used to assess
HRQOL in patients with diabetes. A study by Hirsch
et al. using factor analysis has demonstrated three
factors can be extracted from the measures using the
SF-36, D-39, and Diabetes Treatment Satisfaction
Questionnaire [6], each factor representing a distinct
concept. This would suggest that generic and disease-
speciﬁc instruments may measure different HRQOL
constructs. Previous studies [21,22] also reported that
the correlations of the D-39 and SF-36 subscale
scores were at most moderate, even for among
homogenous subscales, suggesting the constructs in
two instruments were not completely equivalent.
Taken together, these ﬁndings suggest that generic
and disease-speciﬁc instruments for diabetes measures
should be complementary, rather than substitutive.
This makes intuitive sense because disease-speciﬁc
measures are designed primarily to capture the inﬂu-
ence of diabetic control, beyond the impact of mor-
bidities. By contrast, the generic instruments have the
advantage of detecting HRQOL differences inﬂu-
enced by diabetes complications, which may be
confounded by symptoms associated with other con-
ditions, leading to better discriminative capability
than disease-speciﬁc measures.
Although the combined use of generic and disease-
speciﬁc measures may offer a comprehensive picture
for diabetes HRQOL measures, there are still many
unanswered questions. An important issue is how
to reduce the number of items while retaining
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measurement precision. The application of item
response theory (IRT) for instrument development
may be able to provide better answers [54,55]. The
main advantage of IRT is to link and equate items
across instruments on the same metric, which is
helpful in generating an item pool that contains items
with a wide range of item properties. Thus, IRT
allows researcher to tailor an instrument that
matches the latent trait of HRQOL constructs for
individual patients. To this point, however, there have
been few applications of IRT to diabetes HRQOL
measures.
There are a number of limitations to this study.
First, the generalizability of our results may be limited
because our samples were collected from a single
center in Taiwan. Second, we did not examine test–
retest and responsiveness of both instruments. The
interpretation of the score changes (responsiveness)
for HRQOL instruments is important for clinical
practice. As validation of measures is an ongoing
process, future studies should examine these proper-
ties together with diabetes speciﬁcity of measures,
compare the impact of these outcomes in diabetes
with other conditions, and examine the minimal clini-
cally important difference for interpreting meaningful
change.
Conclusions
We demonstrated that for diabetes HRQOL assess-
ment, a diabetes-speciﬁc (the D-39) measure was not
deﬁnitely superior to a generic one (the SF-36). Rather
each instrument had some advantages over the other.
The D-39 and the SF-36 for HRQOL measures appear
to be complementary rather than substitutive. The use
of disease-speciﬁc and generic instruments together
may be the best strategy for measurement of HRQOL
in diabetes. Further studies are suggested to explore
the use of IRT explicitly to link items across different
instruments.
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